Kwaan Hau C, Cull Elizabeth H
Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, and Robert H. Lurie Comprehensive Cancer Center, Olson Pavilion, 710 N.Fairbanks Court, Chicago, IL 60611, USA.
Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, and Robert H. Lurie Comprehensive Cancer Center, Olson Pavilion, 710 N.Fairbanks Court, Chicago, IL 60611, USA.
Best Pract Res Clin Haematol. 2014 Mar;27(1):11-8. doi: 10.1016/j.beha.2014.04.005. Epub 2014 Apr 13.
Coagulopathy is a unique component of the pathology of acute promyelocytic leukaemia (APL). Though many causative factors have been elucidated, therapies to rectify the coagulopathy are far from being realised. Thrombotic and bleeding complications remain the major causes of early deaths. In this chapter, the known causes of abnormalities in haemostatic function, namely the coagulopathy and changes in the fibrinolytic system, will be reviewed. Major risk factors for these complications are identified. Current available measures for correction of the coagulopathy and their effectiveness are critically examined. Unless the coagulopathy can be effectively controlled, bleeding complications will remain an obstacle to achieving a cure for this disease. The issues that need to be addressed in next phase of investigations are also discussed.
凝血功能障碍是急性早幼粒细胞白血病（APL）病理学的一个独特组成部分。尽管已经阐明了许多致病因素，但纠正凝血功能障碍的疗法仍远未实现。血栓形成和出血并发症仍然是早期死亡的主要原因。在本章中，将对已知的止血功能异常原因，即凝血功能障碍和纤溶系统变化进行综述。确定这些并发症的主要危险因素。对目前可用的纠正凝血功能障碍的措施及其有效性进行严格审查。除非凝血功能障碍能够得到有效控制，否则出血并发症仍将是治愈这种疾病的障碍。还讨论了下一阶段研究中需要解决的问题。
